Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Common Equity (2021 - 2025)

Bioregenx (BRGX) has 5 years of Common Equity data on record, last reported at -$3.6 million in Q3 2025.

  • For Q3 2025, Common Equity fell 126.89% year-over-year to -$3.6 million; the TTM value through Sep 2025 reached -$3.6 million, down 126.89%, while the annual FY2024 figure was -$3.4 million, 63.14% down from the prior year.
  • Common Equity reached -$3.6 million in Q3 2025 per BRGX's latest filing, roughly flat from -$3.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $15.1 million in Q1 2024 and bottomed at -$3.7 million in Q2 2025.
  • Average Common Equity over 5 years is $977374.4, with a median of -$2.2 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 2901.09% in 2022, then soared 724.59% in 2024.
  • A 5-year view of Common Equity shows it stood at -$84234.0 in 2021, then plummeted by 2901.09% to -$2.5 million in 2022, then increased by 18.06% to -$2.1 million in 2023, then plummeted by 63.14% to -$3.4 million in 2024, then decreased by 7.93% to -$3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$3.6 million in Q3 2025, -$3.7 million in Q2 2025, and -$3.6 million in Q1 2025.